共 22 条
- [1] Bertilsson L., Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19, Clin Pharmacokinet, 29, 3, pp. 192-209, (1995)
- [2] Masimirembwa C.M., Hasler J.A., Genetic polymorphism of drug metabolizing enzymes in African populations: Implications for the use of neuroleptics and antidepressants, Brain Res Bull, 44, 5, pp. 561-571, (1997)
- [3] Poolsup N., Li Wan Po A., Knight T.L., Pharmacogenetics and psychopharmacotherapy, J Clin Pharm Ther, 25, 3, pp. 197-220, (2000)
- [4] Kirchheiner J., Nickchen K., Bauer M., Wong M.L., Licinio J., Roots I., Brockmoller J., Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response, Mol Psychiatry, 9, 5, pp. 442-473, (2004)
- [5] Lin K.M., Poland R.E., Lau J.K., Rubin R.T., Haloperidol and prolactin concentrations in Asians and Caucasians, J Clin Psychopharmacol, 8, 3, pp. 195-201, (1988)
- [6] Lin K.M., Poland R.E., Nuccio I., Matsuda K., Hathuc N., Su T.P., Fu P., A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients, Am J Psychiatry, 146, 10, pp. 1307-1311, (1989)
- [7] De Haan L., Van Bruggen M., Lavalaye J., Booij J., Dingemans P.M., Linszen D., Subjective experience and D2 receptor occupancy in patients with recent onset schizophrenia treated with low-dose olanzapine or haloperidol: A randomized double-blind study, Am J Psychiatry, 160, 2, pp. 303-309, (2003)
- [8] Lin K.M., Poland R.E., Lesser I.M., Ethnicity and psychopharmacology, Cult Med Psychiatry, 10, 2, pp. 151-165, (1986)
- [9] Mendoza R., Smith M.W., Poland R.E., Lin K.M., Strickland T.L., Ethnic psychopharmacology: The Hispanic and Native American perspective, Psychopharmacol Bull, 27, 4, pp. 449-461, (1991)
- [10] Lin K.M., Smith M.W., Ortiz V., Culture and psychopharmacology, Psychiatr Clin North Am, 24, 3, pp. 523-538, (2001)